Anika Therapeutics Inc (ANIK) — Analysis Summary
Anika Therapeutics Inc (ANIK) has a market cap of $209.83M with year-over-year revenue growth of -5.9%. Net margin stands at -9.6%. The stock trades at a P/E ratio of -19.0.
Key Takeaways
- Revenue changed -5.9% year-over-year
- Net margin of -9.6%
- P/E ratio of -19.0
Compared to other companies in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector, ANIK posted revenue growth of -5.9% and trades at a P/E of -19.0.
Anika Therapeutics Inc (ANIK)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsWatch List
Some caution signals are active and should be weighed alongside the valuation work.
Operating margin at -10.5% — material operating losses
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Employees
235
Headquarters
BEDFORD, MA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.